info@canlab.net

©2017 by CanLab. Proudly created with Wix.com

KCF-18 10 mg

A potential peptide derived from cytokine receptors can bind proinflammatory cytokines as a therapeutic strategy for anti-inflammation

 

The antagonist peptide KCF18 was designed to inhibit cytokine-induced inflammatory response by binding to the cytokines simultaneously. The anti-inflammatory effect of KCF18 is attributed to the reduction of proinflammatory cytokine–receptor interactions on endothelial cells and monocytes, thereby suppressing cytokine mRNA expression and monocyte binding and transmigration.

 

https://www.nature.com/articles/s41598-018-36492-z

 

 

    C$145.00Price